Morinaga Research Reveals That a Combination of 2’-FL and Probiotic with High HMO Utilization Can Address Challenges

The text you provided discusses the role of Human Milk Oligosaccharides (HMOs) in infant and young child health, emphasizing their prebiotic properties, immune system regulation, and contribution to gut microbiota. Here are the key points summarized:

Role of HMOs

1. Health Benefits: HMOs function as prebiotics, prevent infections, and help regulate the immune system in infants.
2. Metabolite Production: They facilitate the production of beneficial metabolites like acetate and aromatic lactic acids (ALAs) through infant-specific bifidobacteria.

Research Focus

• A study by Morinaga Milk Industry assessed the effects of 2’-Fucosyllactose (2’-FL), an abundant HMO, both alone and with Bifidobacterium longum subsp. infantis M-63 on the gut microbiota of infants and young children.

Key Findings

1. Use of 2′-FL:

   • Supplementation led to varied bifidobacterial responses in infants.
   • In combination with B. infantis M-63, 2′-FL consumption was maximized, improving bifidobacteria and metabolite production.

2. Fecal Fermentation Results:

   • Infants on 2′-FL alone showed limited bifidobacteria increase.
   • The combination with B. infantis M-63 consistently enhanced bifidobacteria levels.

3. Young Children’s Microbiota:

   • B. longum, B. breve, and B. catenulatum were common in young children.
   • Infants showed stronger responses to 2’-FL compared to young children, possibly due to microbial competition or less favorable gut conditions.

4. Bifidobacterial Variations:

   • Not all infants and children have bifidobacterial strains that effectively utilize HMOs, impacting health benefits.
   • Children showed a shift in microbial strains post-breastfeeding that may reduce HMO utilization.

5. Importance of Co-Administration:

   • To maximize health benefits of HMOs in both infants and children, the presence of high HMO-utilizing bifidobacteria like B. infantis is crucial.
   • Probiotic supplementation could help in cases where such bacteria are lacking.

Implications

• These findings suggest that optimizing infant formulas with HMOs and suitable probiotics may enhance health outcomes.

Further Research

• Future studies are needed to explore the dynamics of HMO metabolism and gut microbiota adaptation in infants and young children.

Reference

• Source details hint at the study’s publication in Frontiers in Nutrition and provide a DOI for access to the full text.

This summary encapsulates the main points while preserving the essence of the original research findings.